Latest Production News

DataDot Technology Limited reported a 13% revenue increase and a 56% rise in net profit after tax for FY25, driven by growth in its PropertyVAULT insurance services and new distributor partnerships.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Wagners Holding Company Limited reported a robust FY25 with revenue growth led by construction materials and composite fibre technologies, alongside strategic expansion and debt reduction.

Wagners Holding Company Limited reported a solid FY25 with revenue of $431.3 million, driven by growth in construction materials and composite fibre technologies, while reducing net debt by 29%.

Wagners Holding Company Limited reported a 120% increase in net profit after tax for FY25 despite a 10.4% revenue decline, driven by strong segment performance and cost management. The company also declared a higher fully franked final dividend of 3.2 cents per share.

Marvel Gold Limited has restructured its Mali asset sale with Anchises Capital, securing a $250,000 equity injection while revising terms for its Tabakorole Gold Project sale.

Australis Oil & Gas reported a reduced half-year loss and positive cash flow despite lower production, while actively seeking a development partner for its Tuscaloosa Marine Shale assets.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.